PepGen, Inc. (NASDAQ:PEPG) Stock Now Rated “Moderate Buy” by Wall Street Analysts

PepGen, Inc. (NASDAQ:PEPG) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $11.40.

Several brokerages have issued reports on PEPG. Weiss Ratings upgraded shares of PepGen from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 22nd. HC Wainwright reissued a “buy” rating on shares of PepGen in a research note on Wednesday, September 9th. Wall Street Zen lowered shares of PepGen from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Craig Hallum started coverage on shares of PepGen in a report on Tuesday, June 16th. They issued a “buy” rating and a $11.00 price target on the stock.

PepGen Price Performance

NASDAQ:PEPG opened at $2.62 on Monday. The business’s 50-day moving average price is $2.81 and its two-hundred day moving average price is $2.22. PepGen has a twelve month low of $1.31 and a twelve month high of $7.80. The stock has a market cap of $181.46 million, a P/E ratio of -2.00 and a beta of 2.01.

PepGen (NASDAQ:PEPG) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02. On average, equities research analysts expect that PepGen will post -1.11 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Group One Trading LLC purchased a new position in shares of PepGen in the 1st quarter worth about $77,000. Seven Fleet Capital Management LP bought a new position in shares of PepGen during the 1st quarter valued at about $105,000. Rangeley Capital LLC increased its position in shares of PepGen by 88.1% during the 1st quarter. Rangeley Capital LLC now owns 68,096 shares of the company’s stock valued at $121,000 after purchasing an additional 31,896 shares during the last quarter. Persistent Asset Partners Ltd bought a new position in shares of PepGen during the 2nd quarter valued at about $171,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of PepGen during the 2nd quarter valued at about $202,000. 58.01% of the stock is currently owned by hedge funds and other institutional investors.

PepGen Company Profile

PepGen Inc is a clinical-stage biotechnology company developing RNA-based therapeutics for severe neuromuscular and genetic diseases. The company’s programs are designed to address conditions caused by genetic mutations by selectively modifying or restoring the production of disease-related proteins.

PepGen’s technology platform, Enhanced Delivery Oligonucleotide (EDO), uses peptide-conjugated phosphorodiamidate morpholino oligomers to improve the delivery of therapeutic oligonucleotides into muscle and other tissues.